Clinical Research Publications

Research

Published articles by Clinical Research Department staff are listed below. Click on the link to review the Pubmed abstract or free full article where available. Articles on this page are grouped by Recent Publications, Key Publications and Recent Meetings and Clinical Presentations.

Recent Publications

  • A second honeymoon for Parkinson’s disease?
    Tanner, CM.. NEJM 2013 Feb 14;368(7);675-6. PMID: 23406033
    Publication Abstract
  • Which Dyskinesia Scale Best Detects Treatment Response?
    Goetz CG, Stebins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Mov Disord. 2013 Feb 6. PMID: 23390076
    Publication Abstract
  • Caffeine consumption and risk of dyskinesia in CALM-PD.
    Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA; on behalf of the Parkinson Study Group. Mov Disord. 2013 Jan 21. PMID: 23339054
    Publication Abstract
  • Design innovations and baseline findings in a long-term Parkinson’s trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson’s Disease Long-Term Study-1.
    Elm JJ, NINDS NET-PD Investigators. Mov Disord. 2012 Oct;27(12):1513-21. PMID:23079770
    Publication Abstract
  • Genetic Modification of the Association of Paraquat and Parkinson’s Disease.
    Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppine JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A Langston JW, Tanner CM. Movement Disorders, 2012 Oct.  PMID: 23045187
    Publication Abstract
  • Brain organochlorines and Lewy pathology: The Honolulu-Asia aging study.
    Ross GW, Duda JE, Abbott RD, Pellizzari E, Petrovitch H, Miller DB, O’Callaghan JP, Tanner CM, Noorigian JV, Masaki K, Launer L, White LR.. Movement Disorders, 2012 Oct. PMID:22976848 [PubMed – in process]
    Publication Abstract
  • Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease.
    Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern W, Harman J, Lang A, Schwarzschild M, Tanner C, Shoulson I. Mov Disord. 2012 Sep 15;27(11). PMID 22976926.
    Publication Abstract
  • Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants.
    Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P; the Chinese Parkinson Study Group (CPSG). Parkinsonism Relat Disord. 2012 Jun 1. PMID: 22658533.
    Publication Abstract
  • A High-Density Genome-Wide Association Screen of Sporadic ALS in US Veterans.
    Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman SA, Kamel F, Nelson LM, Topol B, Van den Eeden SK, Tanner CM, Cudkowicz ME, Grasso DL, Lawson R, Muralidhar S, Oddone EZ, Schmidt S, Hauser MA.
    PLoS One. 2012;7(3). PMID: 22470424.
    Publication Abstract
  • Meta-analysis of Parkinson’s disease: identification of a novel locus, RIT2.
    Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium. Ann Neurol. 2012 Mar;71(3). PMID: 22451204.
    Publication Abstract
  • Head injury, alpha-synuclein Rep1 and Parkinson’s disease.
    Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM. Annals of Neurology, 2012 Jan;71(1):40-8. PMID: 22275250.
    Publication Abstract
  • Pre-motor features of Parkinson’s disease: the Honolulu-Asia Aging Study experience.
    Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S199-202. PMID: 22166434.
    Publication abstract
  • Genetics meets environment: evaluating gene-environment interactions in neurologic diseases.
    Marras C, Goldman SM Seminars in Neurology, 2011 31(5):553-61. PMID: 22266892.
    Publication abstract
  • Solvent exposures and parkinson disease risk in twins.
    Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM. Annals of Neurol. 2011 Nov 14. PMID: 22083847.
    Publication abstract
  • The relation between depression and parkin genotype: The CORE-PD study.
    Srivastava A, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Caccappolo E, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Alcalay RN, Ross B, Orbe Reilly M, Rezak M, Novak K, Friedman JH, Pfeiffer RD, Marsh L, Hiner B, Merle D, Ottman R, Clark LN, Marder K.. Parkinsonism Relat Disord. 2011 Aug 17. [Epub ahead of print] PMID: 21856206.
    Publication abstract
  • Association of DRD2 and DRD3 polymorphisms with Parkinson’s disease in a multiethnic consortium.
    V. McGuire, S.K. Van Den Eeden, C.M. Tanner, F. Kamel, D.M. Umbach, K. Marder, R. Mayeux, B. Ritz, G.W. Ross, H. Petrovitch, B. Topol, R.A. Popat, S. Costello, A.D. Manthripragada, A. Southwick, R.M. Myers, L.M. Nelson. Journal of the neurological sciences [0022-510X] McGuire yr:2011 Aug 15 vol:307 iss:1-2 pg:22 -29 PMID: 21663922.
    Publication abstract
  • Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease.
    Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Franke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N. PLoS Genetics, 2011 Jun;7(6):e1002141. Epub 2011 Jun 23. PubMed Central PMCID: PMC3121750
    Publication abstract
  • A comparison of treatment thresholds in two large Parkinson’s disease clinical trial cohorts.
    Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators.  Mov Disord. 2009 Dec 15;24(16) PMID: 19908310.
    Publication abstract
  • Predictors of time to requiring dopaminergic treatment in 2 Parkinson’s disease cohorts.
    Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, et. Mov Disord. 2011 Feb 1. Epub ahead of print. PMID: 21287602.
    Publication abstract
  • Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease.
    Popat RA, Van Den Eeden SK, Tanner CM, et al. Eur J Neurol. 2011 Jan 31. Epub ahead of print. PMID: 21281405.
    Publication abstract
  • Rotenone, Paraquat and Parkinson’s Disease.
    Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards M, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Environ Health Perspect 2011 Jan 26. Epub ahead of print. PMID: 21269927.
    Publication abstract
  • Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
    Caccappolo E, Alcalay RN, Mejia-s=Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, et al. J Int Neuropsychol Soc. 2011 Jan: 17(1): 91-100. PMID: 21092386.
    Publication abstract
  • Olfaction in Parkin heterozygotes and compound heterozygotes: The CORE-PD study.
    Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Louis E, Ruiz D, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, et al. Neurology. 2011 Jan 25;76(4):312-3. PMID: 21205674.
    Publication abstract
  • Familial aggregation of Parkinson’s disease in a multiethnic community-based case-control study.
    Shino MY, McGuire V, Van Den Eeden SK, Tanner CM, et al. Mov Disord. 2010 Nov 15;25 (15): 2587-94. PMID: 20842689.
    Publication abstract
  • Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson’s disease.
    Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, Langston JW. Mov Disord. 2010 Oct 30;25(14): 2296-303. PMID: 20976736.
    Publication abstract
  • Comorbid cancer in Parkinson’s disease.
    Lo RY, Tanner CM, Van Den Eeden SK, et al. Mov Disord. 2010 Sep 15;25(12): 1809-17. PMID: 20669266.
    Publication abstract
  • Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease.
    Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, et al. Mov Disord. 2010 Sep 15;25(12): 1801-8. PMID: 20669311.
    Publication abstract
  • Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.
    Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, et al. Arch Neuro. 2010 Sep; 67(9): 1116-22. PMID: 20837857.
    Publication abstract
  • Late-life hemoglobin and the incidence of Parkinson’s disease.
    Abbott RD, Ross GW, Tanner CM, et al. Neurobiol Aging. 2010 Aug 13. (Epub ahead of print) PMICD:PMC3006667.
    Publication abstract
  • Teaching program for the Movement Disorder Society-sponspored revision of the Unified Parkinson’s Disease Rating Scale: (MDS-UPDRS).
    Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Mov Disord. 2010 Jul 15; 25(9): 1190-4. PMID: 20629138.
    Publication abstract
  • Predictors of Parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.
    Marder KS, Tang MX, mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, et al. Arch Neurol. 2010 Jun; 67(6): 731-8. PMID: 20558392.
    Publication abstract
  • Trichloroethylene and Parkinson’s disease: dissolving the puzzle.
    Goldman SM. Expert Rev Neurother. 2010 Jun;10(6):835-7. PMID: 20518596.
    Publication abstract
  • Reliability and Validity of Two Self-administered Questionnaires for Screening Restless Legs Syndrome in Population-based Studies.
    Popat RA, Van Den Eeden SK, Tanner CM, et al. Sleep Med. 2010 Feb; 11(2): 154-60. PMID: 20089446.
    Publication abstract
  • Self-report of Cognitive Impairment and Mini-mental State Examination Performance in PRKN, LRRK2, and GBA Carriers with Early Onset Parkinson’s disease.
    Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, et al. J Clin Exp Neuropsychol. 2010 Feb 24: 1-5. PMID: 20182943.
    Publication abstract
  • Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease.
    Ascherio A, Lewitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; for the Parkinson Study Group DATATOP Investigators. Arch Neurol. 2009 Dec;66(12): 1460-8. Epub. PMID: 19822770.
    Publication abstract
  • Motor Phenotype of LRRK2 G20195S carriers in early onset PD.
    Alcalay R, Clark L, Mejia-Santana H, Tang M, Rosado L, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, et al. Arch Neurol. 2009 Dec; 66(12): 1517-22. PMID: 20008657.
    Publication abstract
  • Health Related Quality of Life in Early Parkinson’s Disease: Impact of Motor and Non-motor Symptoms, Results from Chinese Levodopa Exposed Cohort.
    Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P; the Chinese Parkinson Study Group. Parkinsonism Relat Disord. 2009 Dec; 15(10): 767-771. Epub 2009 Jun 23. PMID: 19553154.
    Publication abstract
  • Clinical Features in Early Parkinson Disease and Survival.
    Lo RY, Tanner CM, Albers KB, Leimpeter AD, Fross RD, Bernstein AL, McGuire V, Quesenberry CP, Nelson LM, Van Den Eeden SK. Arch Neurol. 2009 Nov; 66(11): 1353-8. PMID: 19901166.
    Publication abstract
  • A Longitudinal Program for Biomarker Development in Parkinson’s disease: a feasibility study.
    Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz Shoulson I; Parkinson Study Group LABS-PD Investigators. Mov Disord. 2009 Oct 30; 24(14): 2081-90. PMID: 19691116.
    Publication abstract
  • Occupation and risk of parkinsonism: a multicenter case-control study.
    Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW. Arch Neurol. 2009 Sep; 66(9): 1106-13. PMID: 19752299.
    Publication abstract
  • Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants.
    Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study Group. Neurology. 2009 Aug 4;73(5):385-92. PMID: 19652143.
    Publication abstract
  • Bowel movement frequency in late-life and sunstantia nigra neuron density at death.
    Petrovitch H, Abbott RD, Ross GW, Nelson J, Masaki KH, Tanner CM, Launer LJ, White LR. Mov Disord. 2009 Feb 15;24(3): 371-6. PMID: 20518596.
    Publication abstract
  • Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007.
    Jeff Bronstein,1 Paul Carvey,2 Honglei Chen,3 Deborah Cory-Slechta,4 Donato DiMonte,5 John Duda,6 Paul English,7 Samuel Goldman,5 Stephen Grate,8 Johnni Hansen,9 Jane Hoppin,3 Sarah Jewell,5 Freya Kamel,3 Walter Koroshetz,10 James W. Langston,5 Giancarlo Logroscino,11 Lorene Nelson,12 Bernard Ravina,13 Walter Rocca,14 George W. Ross,15 Ted Schettler,16 Michael Schwarzschild,17 Bill Scott,18 Richard Seegal,19 Andrew Singleton,20 Kyle Steenland,21 Caroline M. Tanner,5 Stephen Van Den Eeden,22 and Marc Weisskopf23. Environ Health Perspect. 2009 January; 117(1): 117–121. PMID: 19165397.
    Publication abstract
  • Use of antihypertensives and the risk of Parkinson disease.
    Ascherio A, Tanner CM. Neurology. 2009 Apr 15;70(16 Pt 2):1438-44. PMID: 19204275.
    Publication abstract

Key Publications

  • DATATOP: a multi-center clinical trial in early Parkinson’s disease.
    Parkinson Study Group. Arch Neurol 1989;46:1052-1060.
  • Environmental factors and Parkinson’s disease: a case control study in China.
    Tanner CM, Chen B, Wong W, Peng M, Liu Z, Liang X, Kao LC, Gilley DW, Goetz CG, Schoenberg BS. Neurology 1989;39:660-664. PMID: 2710356.
    Publication abstract
  • Parkinson’s disease in twins: An etiologic study.
    Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW: JAMA 1999;281(4):341-46. PMID: 9929087.
    Publication abstract
  • Epidemiology of Movement Disorders.
    Tanner CM, Goldman SM. Current Opinion in Neurology 1994;7:340-345. PMID: 7952243.
    Publication abstract
  • The Association of Coffee and Caffeine Intake with the Risk of Parkinson’s Disease.
    Ross GW, Abbott RD, Petrovich H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb, JD, White LR, Popper J. JAMA 2000: 283(20):2674-2679. PMID: 10819950.
    Publication abstract
  • Essential tremor in twins: An assessment of genetic vs. environmental determinants of etiology. 
    Tanner CM, Goldman SM, Lyons KE, Aston DA, Tetrud JW, Welsh MD, Langston JW, Koller WC. Neurology 2001; 57(8):1389-1391. PMID: 11673577.
    Publication abstract
  • Smoking and Parkinson’s disease in twins.
    Tanner CM, Goldman SM, Aston D, Ottman R, Ellenberg J, Mayeaux R, Langston JW. Neuorology 2002; 58(4): 581-588. PMID: 11865136.
    Publication abstract
  • Incidence of Parkinson’s disease (PD): Variations by age, gender and race/ethnicity.
    Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Am J Epidemiol 2003; 157(11):1015-1022. PMID: 12777365.
    Publication abstract
  • Is the cause of Parkinson’s disease environmental or hereditary? Evidence from twin studies. 
    Tanner CM. Advances in Neurology 2003;91:133-142. PMID: 12442672.
    Publication abstract
  • Head Injury and Parkinson’s Disease Risk in Twins..
    Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Annals of Neurology 2006;60:65-72. PMID: 16718702.
    Publication abstract
  • Epidemiology of Parkinson’s disease..
    Kasten M, Chade A, Tanner CM. Handb Clin Neurol. 2007;83:129-51. (in process). PMID: 18808913.
  • Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. .
    Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, Comyns K, Goldman S, Korell M, Langston J, Ross G, Sandler D. Am J Epidemiology 2007;165(4):364-365. PMID: 17116648.
    Publication abstract
  • Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.
    Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina RM, Schifitto G, Siderowf A, Tanner CM. Neurology 2007;68(5):384-386. PMID: 17082464.
    Publication abstract

Recent Meetings and Clinical Presentations

  • Parkinson’s Disease Risk is Associated with Variants in Genes that Bind Bacterial Cell-Wall Peptidoglycan.
    Goldman SM, Jewell S, Meng C, Ross GW, Chade A, Kasten M, Bhudhikanok GS, Comyns K, Korell M, Langston JW, Tanner CM. Neurology, 2013: P05.051
  • Incidence of Primary Torsion Dystonia in a Multiethnic Population.
    Tanner CM, Albers KB, Goldman SM, Klingman J, Lo RY, Marras C, Leimpeter AD, Fross R, Gu Z, Smit R, deKlein A, Bhudhikanok GS, Ozelius L, Bressman S, Sanders-Pullman R, Comella C, Nelson LM, Van Den Eeden SK. Neurology, 2013: S53.001.
  • The Benefits of Federally Funded Research: the Environment and Parkinson’s Disease.
    Goldman, SM. Presented at the Parkinson’s Action Network Leadership Forum, Washington, D.C., 2012
  • Genes, Environment and PD: the search for causes.
    Goldman, SM. Presented at the Virginia Commonwealth University, Parkinson’s Disease Community Education Day, Richmond, Virginia, 2012
  • Diagnostic Error in Primary Torsion Dystonia.
    Tanner CM, Van Den Eeden SK, Goldman SM, Lo RY, Marras C, Albers KB, Leimpeter AD, Fross R, Comyns K, Gu Z, Smit R, deKlein A, Ozelius L, Bressman S, Sanders-Pullman R, Comella C, Nelson LM, Klingman J. Annals of Neurology, 2012: T1759.
  • Seborrheic Dermatitis and Risk of Future Parkinson’s Disease (PD).
    Tanner CM, Albers KB, Goldman S, Fross R, Leimpeter AD, Klingman J, Van Den Eeden S.. Neurology, 78: S42.001, 2012.
  • Paraquat Use Modifies the Association of Head Injury and Parkinson’s Disease (PD).
    Goldman SM, Kamel F, Bhudhikanok GS, Korell M, Meng C, Comyns K, Umbach DM, Hoppin JA, Ross GW, Marras C, Kasten M, Chade A, Sandler DP, Blair A, Langston JW, Tanner CM. Neurology, 78: S42.003, 2012.
  • Risk of Parkinson’s disease (PD) associated with the herbicide paraquat is attenuated by high dietary intake of polyunsaturated fatty acids (PUFAs).
    Kamel F, Richardson G, Umbach DM, Richards M, Bhudhikanok GS, Blair A, Chade A, Comyns K, Goldman SM, Hoppin JA, Kasten M, Korell M, Marras C, Meng C, Ross GW, Langston JW, Sandler DP, Tanner CM. Neurology, 78: S42.004, 2012.
  • Trichloroethylene exposure and Parkinson’s disease risk.
    Goldman, SM. Parkinsonism and Related Disorders, 18(Suppl 2): S89, 2012
  • Hierarchical cluster analysis of cortical pathology suggests pathologic heterogeneity of dementia in Parkinson disease.
    Dickson DW, Orr C, Murray ME, Pahwa R, Lyons K, Goldman SM, Langston JW, Wszolek ZK, Uitti RJ, Graff-Radford N, Ferman T Journal of Neuropathology & Experimental Neurology, 70 (6): 498, 2011.
  • Genetics Meets Environment: Evaluating Gene-Environment Interaction in Neurological Disease.
    Goldman, SM. Presented at the American Academy of Neurology Annual Meeting, Genetics in Neurology Course, Honolulu, HI, 2011
  • California Parkinson’s disease registry pilot project in Santa Clara County, CA.
    Tanner CM, Jewell S, English P, Siegel M, Roucoux D, Wasson G, Wasson A, Van Den Eeden S, Meng C, Comyns K, Albers K, Goldman SM, Nelson L, Topol B, Bronstein J, Langston JW, Ritz B. Neurology, 76 (Suppl 4): A122, 2011.
  • Alpha-synuclein (SNCA) Rep1 Genotype Modifies the Association of Closed Head Injury (CHI) with Parkinson’s Disease (PD).
    Goldman SM, Kamel F, Bhudhikanok G, Meng C, Umbach D, Hoppin JA, Ross GW, Korell M, Marras C, Kasten M, Chade A, Blair A, Sandler DP, Langston JW, Tanner CM. Annals of Neurology, 68 (Suppl 14): S16, 2010.
  • PON1 Polymorphisms, Organophosphate Exposure, And Parkinson’s Disease (PD).
    Kamel F, Goldman SM, Umbach D, Hoppin J, Richards M, Korell M, Bhudhikanok G, Meng C, Ross GW, Blair A, Langston JW, Sandler D, Tanner C. Neurotoxicology, 2010.
  • Trichloroethylene Exposure and Parkinson´s Disease Risk.
    Goldman, SM. Presented at the XIX World Congress on Parkinson’s Disease and Related Disorders, Shanghai, China, 2011
  • Heart rate variability and pre-motor Parkinson’s disease.
    Goldman, SM. Presented at the Michael J. Fox Foundation Therapeutics Conference, New York, NY, 2010
  • Rotenone, Paraquat and Parkinson’s Disease (PD).
    Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok G, Kasten M, Chade A, Comyns K, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach D, Blair A, Sandler DP, Langston JW. Annals of Neurology 2010; 68 Suppl 14): S17.
  • Depression among Carriers and Non Carriers of Parkin Mutations.
    Srivastava Anil, Tang Ming, Louis Elan, Mejia-Santana Helen, Ottman Ruth, Rosado Llency, Marder Karen, Commela Cynthia, Bressman Susan, Nance Martha, Siderowf Andrew, Jennings Danna, Colcher Amy, Scott William, Waters Cheryl, Cote Lucien, Andrews Howard, Tanner Caroline, et al. Neurology 2010; 74(9) Suppl 2: S08.005.
  • Parkinson’s Disease Risk is Increased in Discordant Twins Exposed to Specific Solvents.
    Goldman Samuel.M, Tanner Caroline.M, Meng Cheryl, et al. Neurology 2010; 74(9) Suppl 2: S03.005.
  • Late-life Hemoglobin and the Incidence of Parkinson’s Disease: The Honolulu- Asia Aging Study.
    Petrovitch Helen, Abbott Robert, Ross Web, Tanner Caroline, et al. Neurology 2010; 74(9) Suppl 2: S03.004.
  • Parkinson’s Disease (PD) Increases Risk for Mild Cognitive Impairment (MCI).
    Adler Charles.H, Hentz Joseph.G, Shill Holly A, Sabbagh Marwan. N, Connor Donald.J, Evidente Virgilio Gerald, Driver-Dunckley Erika, Tanner Caroline, et al. Neurology 2010; 74(9) Suppl 2: P01.218.
  • Follow-up of Persons with Neurologic Diseases (Found): Remote Follow-up- A Practical Approach To Maintain Continuous Contact. 
    Tanner Caroline.M; Meng Cheryl.C, Shoulson Ira, et al. Neurology 2010; 74(9) Suppl 2: P01.163
  • Relationship of Brain Organochlorine Levels with Lewy Pathology: The Honolulu- Asia Aging Study. 
    Ross Web, Duda John E, Petrovitch Helen, Pellizzari Edo, He Qimei, Miller Diane B, O’Callaghan James P, Tanner Caroline M, et al. Neurology 2010; 74(9) Suppl 2: P01.157.
  • Can the EKG be used to identify prodromal PD? Assessment of heart rate variability (HRV) during wakefulness in patients with RBD.
    Valappil R, Black J.E, Broderick M.J, Carrillo O, Frenette E, Sullivan S, Tanner CM, Langston JW. Movement Disorders 2009, Vol.24, suppl. 1: u-234
  • A longitudinal program for biomarker development in parkinson’s disease.
    Ravina B, Tanner C, DiEuliis D, Flagg E, Shoulson I, Parkinson Study Group, LABS-PD Investigators (Rochester, New York). Movement Disorders 2009, Vol.24, suppl. 1: We-192
  • Motor Phenotype of LRRK2 G20195S carriers in early onset PD.
    Alcalay R, Clark L, Mejia-Santana H, Tang M, Rosado L, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, et al. Movement Disorders 2009, Vol.24, suppl. 1: Mo-86
  • Demographic and Clinical Characteristics of LRRK2 G2019S Carriers in Early Onset PD.
    Alcalay Roy N, Clark Lorraine N, Mejia-Santana Helen, Tang Ming, Rosado Llency E, Louis Elan, Comella Cynthia, Colcher Amy, Jennings Danna, Nance Martha, Bressman Susan, Scott William K, Tanner CM, et al. Neurology 2009; 72(11) Suppl 3: P08.095
  • Late-life Cognitive Function in Non-Demented Disease. .
    Ross G. W, Abbott Robert D, Petrovitch Helen, Tanner CM, Masaki Kamal, White Lon R. Neurology 2009; 72(11) Suppl 3:P04.020
  • Smoking, Genes and Risk for Parkinson’s Disease. .
    Gu zhuqin, Tanner CM, Chan Piu.. Neurology 2009; 72(11) Suppl 3: P09.012
  • Minimum Incidence of Primary Spasmodic Dysphonia.
    Lo RY, Tanner CM, Albers KB, Leimpeter AD, Fross RD, Comyns K, Liang G, Bernstein AL, Klingman J, Goldman S, Ozelius L, Marras C, Bressman SB, Comella CL, Risch N, Nelson LM, Ludlow CL, McGee BS, Van Den Eeden SK. Neurology 2009; 72(11) Suppl 3: A273
  • Late-Life Cognitive Function in Non-Demented Elderly Men and the Incidence of Parkinson’s Disease.
    Ross GW, Abbott RD, Petrovitch H, Tanner CM, Masaki K, White LR. Neurology 2009; 72(11) Suppl 3: A170
  • Demographic and Clinical Characteristics of LRRK2 G2019S Carriers in Early Onset PD.
    Alcalay RN, Clark LN, Mejia-Santana H, Tang M, Rosado LE, Luis E, Comella C, Colcher A, Station M, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Micket S, Andrews H, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Caccappolo EZ, Hiner B, Siderowf A, Ottman R, Marder K. Neurology 2009; 72(11) Suppl 3: A389
  • The Effect of Cigarette Smoking on Survival in Parkinson’s Disease.
    Van Den Eeden SK, Albers KB, Nelson LM, Lo R, Leimpeter AD, Quesenberry CP, Bernstein AL, McGuire V, Tanner CM. Neurology 2009; 72(11) Suppl 3: A450
  • Smoking , Genes and Risk for Parkinson’s Disease
    Gu Z, Tanner C, Chan P.. Neurology 2009; 72(11) Suppl 3: A450
  • a-Synuclein (SNCA) Genotype Modifies the Association between Head Injury and Parkinson’s Disease (PD). 
    Goldman SM, Kamel F, Bhudhikanok G, Korell M, Sterling L, Hoppin J, Umbach D, Ross GW, Sandler DP, Blair A, Langston JW, Tanner CM. Neurology 2009; 72(11) Suppl 3: A258

Center of Excellence

The Parkinson’s Institute and Clinical Center is designated as one of 45 worldwide Centers of Excellence for Parkinson’s treatment and research. This is a distinction awarded by the Parkinson’s Foundation.

Questions about making a donation? Please call (650) 770-0201.

Email News and Updates

Join our mailing list to receive the latest news and updates from our team.

Parkinson's Institute and Clinical Center
2500 Hospital Drive, Building 10, Suite 1 | Mountain View, CA 94040
(650) 770-0201 main | (650) 770-0204 fax (secure clinic fax)

Federal Tax ID # 94-3061594